Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib adjunctive treatment for depression symptoms and impulse control in borderline personality disorder with major depressive disorder
IRCT20230607058400N5Phase 2Recruiting
- Sponsor
- Golestan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of celecoxib in borderline personality disorder (BPD) and major depressive disorder (MDD) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Change in impulse control. Started Oct 2026; status: recruiting.
02
Drugs
celecoxib
03
Conditions
borderline personality disorder (BPD)major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20230607058400N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230607058400N5.